Seamless Therapeutics
Seamless Therapeutics is a preclinical German biotech developing programmable recombinase gene editing technology as an alternative to CRISPR/Cas, licensing its platform to pharmaceutical partners for large-fragment DNA corrections in genetic diseases, with Eli Lilly as its lead partner for hearing loss treatments.
- Company typePrivate
- Founded2023
- HeadquartersDresden, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Seamless Therapeutics does
Seamless Therapeutics is a preclinical-stage German biotechnology company developing a proprietary gene editing platform based on programmable recombinases. Founded in 2023 and headquartered in Dresden, Germany with a US office in Lexington, Massachusetts, the company is building an alternative to CRISPR/Cas gene editing that enables precise, large DNA fragment insertions or deletions anywhere in the genome without introducing additional mutations. The core technology was developed by Prof. Frank Buchholz at TU Dresden and refined by co-founder Felix Lansing during his PhD research, resulting in 7 foundational patents and licensed IP rights that anchor the platform.
The company's product strategy centers on a single platform technology — site-specific recombinases that can be programmed for specific therapeutic targets — which it is applying to develop a pipeline of disease-modifying candidates across a broad spectrum of genetic disease indications, with hearing loss as the lead area via a major partnership. Seamless does not sell products directly; instead, it generates revenue through licensing and research collaboration agreements with pharmaceutical partners, receiving upfront payments, committed R&D funding, development and commercial milestones, and tiered royalties on approved products. Its primary customer relationship is a January 2026 global research collaboration and licensing agreement with Eli Lilly valued at up to $1.12 billion for hearing loss treatments.
The company is venture-backed, having closed a $12.5 million seed round in March 2023 co-led by Wellington Partners and Forbion, with additional non-dilutive support from the German government's BMBF GO-Bio program and UCB Ventures as a listed investor. Leadership includes President and CEO Albert Seymour (formerly of Homology Medicines, Shire, and Pfizer) and Chief Development Officer Deborah Kinch (formerly of Homology Medicines and Biogen), reflecting a deliberate build-out of US-based drug development expertise to support the platform's transition toward first-in-human clinical trials.
Seamless Therapeutics firmographics
Firmographics- Name
- Seamless Therapeutics
- Legal name
- Seamless Therapeutics GmbH
- Website
- https://seamlesstx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Seamless Therapeutics is a preclinical German biotech developing programmable recombinase gene editing technology as an alternative to CRISPR/Cas, licensing its platform to pharmaceutical partners for large-fragment DNA corrections in genetic diseases, with Eli Lilly as its lead partner for hearing loss treatments.
- Ownership category
- akta.pro rank
Seamless Therapeutics industry classification
Industry- Product category
- Gene Editing Biotechnology Platform
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD)
- akta.pro secondary industries
- Gene Therapy for Rare/Monogenic Diseases (HLAAACAE), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
Keywords
Where Seamless Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Dresden
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Seamless Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Research Collaboration Agreements: Seamless enters into strategic research collaborations with pharmaceutical companies where they design and program site-specific recombinases for specific therapeutic applications. The company receives upfront payments, committed R&D funding, and potential milestone payments.
- Licensing and Milestone Payments: License agreements that provide exclusive rights to pharmaceutical partners for preclinical, clinical development, and commercialization. Seamless receives upfront payments, R&D funding, development and commercial milestones, and tiered royalties on approved products.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Seamless Therapeutics product offering
Product offeringCore offering
Seamless Therapeutics develops a proprietary programmable recombinase-based gene editing platform that enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. The platform is being applied to build a pipeline of disease-modifying gene therapy candidates, with the lead focus on hearing loss in collaboration with Eli Lilly, and is monetized through licensing and research collaboration agreements with pharmaceutical partners.
Product overview
Seamless Therapeutics operates as a single-platform biotechnology company developing a proprietary programmable recombinase gene editing technology. Their core platform enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations, representing an alternative approach to CRISPR/Cas gene editing. The company is applying this technology to develop a pipeline of disease-modifying product candidates across a broad spectrum of genetic disease indications. As of 2026, the company has entered a collaboration with Eli Lilly to develop treatments for hearing loss using this platform technology.
Differentiator
Problem solved
Functional benefit
Products and services
- Programmable Recombinase Gene Editing Platform A proprietary gene editing technology platform based on programmable recombinases that enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. The platform uses site-specific recombinases to correct gene mutations and is being developed for treating genetic diseases, including hearing loss via the Eli Lilly collaboration.
Quantifiable outcome
- Potential $1.12 billion deal value from Eli Lilly partnership including upfront, R&D funding, and milestone payments
- +1 more outcomes
Companies that use Seamless Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles1 record
Seamless Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Seamless Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Eli LillycoreEli Lilly entered into a global research collaboration and licensing agreement with Seamless Therapeutics to develop programmable recombinase-based gene-editing treatments for hearing loss. Seamless designs and programs site-specific recombinases to correct gene mutations, while Lilly gains exclusive license to advance candidates through preclinical and clinical development and commercialization. Deal could exceed $1.12 billion in total payouts for Seamless across upfront payments, R&D funding, and milestone terms.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Seamless Therapeutics competitors and assessment
Company assessmentDirect peers
- Beam Therapeutics: Clinical-stage biotechnology company developing precision genetic medicines using base editing technology. Directly comparable to Seamless as a next-generation gene editing platform pursuing therapeutic applications, with differentiated editing chemistry targeting similar disease indications.
- Editas Medicine: Clinical-stage gene editing company developing CRISPR-based medicines for serious diseases. Comparable to Seamless as a genome editing platform pursuing in vivo and ex vivo therapeutic applications, with overlapping target indications in genetic diseases.
- Verve Therapeutics: Clinical-stage biotechnology company developing in vivo base editing treatments for cardiovascular disease. Comparable to Seamless as a gene editing platform pursuing in vivo therapeutic applications, with focus on durable treatments for genetic diseases.
- Precision BioSciences: Clinical-stage biotechnology company developing ARCUS gene editing platform for in vivo and ex vivo therapeutic applications. Directly comparable to Seamless as a novel gene editing platform pursuing therapeutic applications with differentiated editing architecture.
- Prime Medicine: Clinical-stage biotechnology company developing prime editing technology for precise gene corrections. Directly comparable to Seamless as a next-generation gene editing platform seeking to expand the scope of addressable genetic edits beyond traditional CRISPR/Cas approaches.
- Intellia Therapeutics: Clinical-stage biotechnology company developing in vivo CRISPR/Cas9-based gene editing therapies. Directly comparable to Seamless as a genome editing platform company pursuing therapeutic applications across multiple genetic diseases, with overlapping modalities despite using a different editing architecture.
- CRISPR Therapeutics: Clinical-stage biopharmaceutical company focused on CRISPR/Cas9 gene-editing therapies for hemoglobinopathies, oncology, and regenerative medicine. Directly comparable to Seamless as a genome editing platform company pursuing multiple therapeutic indications through a core editing technology.
Emerging players
- Tessera Therapeutics: Preclinical-stage biotechnology company developing Gene Writing technology for precise genomic alterations. Comparable to Seamless as an emerging next-generation gene editing platform pursuing large DNA modifications for therapeutic applications.
- Ensoma: Preclinical-stage biotechnology company developing in vivo gene editing and delivery technology for genomic medicines. Comparable to Seamless as an emerging gene editing platform, and notably a current board affiliation of Seamless CEO Albert Seymour, suggesting direct professional overlap in the field.
Broad incumbents
- Sangamo Therapeutics: Clinical-stage biotechnology company developing zinc finger nuclease-based genome editing and gene therapy. Comparable to Seamless as a pioneering gene editing platform pursuing therapeutic applications across multiple genetic disease indications with a non-CRISPR editing approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Seamless Therapeutics social profiles
Digital presenceSeamless Therapeutics compliance and trust
Trust signalCompliance1 record
Seamless Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seamless Therapeutics leadership team
Management profileNumber of profiles
Profiles11 records
Seamless Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seamless Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seamless Therapeutics
What does Seamless Therapeutics do?
Seamless Therapeutics develops a proprietary programmable recombinase-based gene editing platform that enables large, precise DNA deletions or insertions anywhere in the genome without introducing additional mutations. The platform is being applied to build a pipeline of disease-modifying gene therapy candidates, with the lead focus on hearing loss in collaboration with Eli Lilly, and is monetized through licensing and research collaboration agreements with pharmaceutical partners.
Is Seamless Therapeutics a public or private company?
Seamless Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Seamless Therapeutics founded?
Seamless Therapeutics was founded in 2023. It employs 11 to 50 people.
Where is Seamless Therapeutics based?
Seamless Therapeutics is headquartered in Dresden, Germany, in the Europe region.
How does Seamless Therapeutics make money?
Two revenue lines are on record. Research Collaboration Agreements are the primary driver. The others are licensing and Milestone Payments.
Who are Seamless Therapeutics's main competitors?
Direct peers on record are Beam Therapeutics, Editas Medicine, Verve Therapeutics, Precision BioSciences, Prime Medicine, Intellia Therapeutics and CRISPR Therapeutics. Emerging players are Tessera Therapeutics and Ensoma. Sangamo Therapeutics is listed as a broad incumbent.
Does Seamless Therapeutics have an API?
No public API is recorded for Seamless Therapeutics.
What industry is Seamless Therapeutics in?
Seamless Therapeutics's product category is Gene Editing Biotechnology Platform. Its primary akta.pro industry code is HLAAACAD, Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 325414 and its SIC code is 2836.